Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Milton S. Hershey Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06541262CT.gov Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | — | Recruiting | — | — | — |
NCT04861948CT.gov IBI188 Combination Therapy in Solid Tumors | — | Terminated | — | — | — |
NCT01154816CT.gov Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | — | Completed | — | — | — |
NCT00038207CT.gov Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (+)-Vincristine (this asset) | Milton S. Hershey Medical Center | P2 | BB · 65 |
| Ipilimumab | Children's National Research Institute | P2 | BB |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | B |
| Irinotecan | Milton S. Hershey Medical Center | P2 | B |
| Etoposide | Eisai Limited | P2 | B |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | B |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
+42 more in the Osteosarcoma cohort
Other indications for (+)-Vincristine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P4 | BBB · 78 |
| Anaplastic Large Cell Lymphoma | — | P4 | BBB · 78 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (+)-Vincristine in Osteosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vincristine-osteosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →